Display options
Cite
Lucana MC, Arruga Y, Petrachi E, et al. Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics. Pharmaceutics. 2021;13(12)doi: 10.3390/pharmaceutics13122065.
Lucana, M. C., Arruga, Y., Petrachi, E., Roig, A., Lucchi, R., & Oller-Salvia, B. (2021). Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics. Pharmaceutics, 13(12), . https://doi.org/10.3390/pharmaceutics13122065
Lucana, Maria C, et al. "Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics." Pharmaceutics vol. 13,12 (2021). doi: https://doi.org/10.3390/pharmaceutics13122065
Lucana MC, Arruga Y, Petrachi E, Roig A, Lucchi R, Oller-Salvia B. Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics. Pharmaceutics. 2021 Dec 02;13(12). doi: 10.3390/pharmaceutics13122065. PMID: 34959346; PMCID: PMC8708026.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2021 Dec 02;13(12). doi: 10.3390/pharmaceutics13122065.

Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics.

Pharmaceutics

Maria C Lucana, Yolanda Arruga, Emilia Petrachi, Albert Roig, Roberta Lucchi, Benjamí Oller-Salvia

Affiliations

  1. Grup d'Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull, 08017 Barcelona, Spain.

PMID: 34959346 PMCID: PMC8708026 DOI: 10.3390/pharmaceutics13122065

Abstract

Peptides show high promise in the targeting and intracellular delivery of next-generation bio- and nano-therapeutics. However, the proteolytic susceptibility of peptides is one of the major limitations of their activity in biological environments. Numerous strategies have been devised to chemically enhance the resistance of peptides to proteolysis, ranging from

Keywords: cell-penetrating peptides; cyclic peptides; enantio; protease resistance; proteolysis; retro-enantio; retro-inverso; targeting peptides

References

  1. J Nat Prod. 2007 May;70(5):741-6 - PubMed
  2. Angew Chem Int Ed Engl. 2015 Mar 2;54(10):3023-7 - PubMed
  3. Int J Nanomedicine. 2018 Nov 29;13:8119-8135 - PubMed
  4. Angew Chem Int Ed Engl. 2013 Jan 2;52(1):254-69 - PubMed
  5. Bioconjug Chem. 2017 Oct 18;28(10):2507-2513 - PubMed
  6. Chem Commun (Camb). 2018 Nov 8;54(90):12738-12741 - PubMed
  7. Chem Soc Rev. 2016 Aug 22;45(17):4690-707 - PubMed
  8. J Pept Res. 2005 Jun;65(6):550-5 - PubMed
  9. J Biol Chem. 2002 Dec 6;277(49):47891-7 - PubMed
  10. ACS Appl Mater Interfaces. 2016 Jun 1;8(21):13232-41 - PubMed
  11. AAPS J. 2015 Jan;17(1):134-43 - PubMed
  12. Chem Rev. 2019 Sep 11;119(17):9971-10001 - PubMed
  13. Mol Immunol. 1997 Feb;34(2):157-63 - PubMed
  14. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14598-603 - PubMed
  15. Methods Mol Biol. 2019;2001:17-40 - PubMed
  16. J Control Release. 2010 Apr 19;143(2):265-73 - PubMed
  17. Mol Pharm. 2014 Sep 2;11(9):3210-22 - PubMed
  18. J Biol Chem. 2001 Feb 23;276(8):5836-40 - PubMed
  19. Chem Rev. 2019 Sep 11;119(17):9836-9860 - PubMed
  20. Theranostics. 2016 Jun 15;6(9):1403-14 - PubMed
  21. Bioconjug Chem. 2017 Aug 16;28(8):2167-2179 - PubMed
  22. Angew Chem Int Ed Engl. 2017 Feb 1;56(6):1525-1529 - PubMed
  23. J Med Chem. 2021 May 13;64(9):5802-5815 - PubMed
  24. Nat Chem. 2017 Aug;9(8):762-771 - PubMed
  25. Chem Rev. 2019 Sep 11;119(17):9861-9914 - PubMed
  26. Chem Soc Rev. 2014 May 21;43(10):3575-94 - PubMed
  27. Bioorg Med Chem Lett. 2019 Apr 1;29(7):896-900 - PubMed
  28. ACS Appl Mater Interfaces. 2017 Jul 26;9(29):24462-24475 - PubMed
  29. Chem Rev. 2019 Sep 11;119(17):10241-10287 - PubMed
  30. J Am Chem Soc. 2019 Oct 16;141(41):16374-16381 - PubMed
  31. Angew Chem Int Ed Engl. 2018 Apr 16;57(17):4756-4759 - PubMed
  32. Sci Rep. 2016 Nov 07;6:36617 - PubMed
  33. PLoS One. 2014 Jul 24;9(7):e103336 - PubMed
  34. Mol Pharm. 2018 Feb 5;15(2):592-601 - PubMed
  35. Bioconjug Chem. 2007 Jan-Feb;18(1):50-60 - PubMed
  36. Nat Rev Drug Discov. 2020 Jun;19(6):389-413 - PubMed
  37. Angew Chem Int Ed Engl. 2015 Feb 2;54(6):1950-3 - PubMed
  38. PLoS Biol. 2004 Feb;2(2):E36 - PubMed
  39. Biomol Ther (Seoul). 2012 Jan;20(1):19-26 - PubMed
  40. Angew Chem Int Ed Engl. 2016 Aug 16;55(34):9894-7 - PubMed
  41. J Biol Chem. 1996 Jul 26;271(30):18188-93 - PubMed
  42. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):572-5 - PubMed
  43. J Control Release. 2016 Dec 10;243:86-98 - PubMed
  44. Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13003-8 - PubMed
  45. Mol Pharm. 2014 Oct 6;11(10):3261-8 - PubMed
  46. ACS Appl Mater Interfaces. 2016 Nov 9;8(44):29977-29985 - PubMed
  47. J Biol Chem. 2017 Jan 20;292(3):847-861 - PubMed
  48. Angew Chem Int Ed Engl. 2015 Mar 23;54(13):3967-72 - PubMed
  49. Angew Chem Int Ed Engl. 2015 Jul 27;54(31):8896-927 - PubMed
  50. Biopolymers. 2013 Nov;100(6):662-74 - PubMed
  51. Curr Protoc Chem Biol. 2011 Sep 1;3(3):99-117 - PubMed
  52. Ann Maxillofac Surg. 2011 Jul;1(2):150-4 - PubMed
  53. RSC Med Chem. 2021 Jun 29;12(8):1325-1351 - PubMed
  54. Molecules. 2018 Jun 26;23(7): - PubMed
  55. Biomaterials. 2012 Oct;33(29):7194-205 - PubMed
  56. J Control Release. 2017 Mar 28;250:62-76 - PubMed
  57. ACS Nano. 2018 Feb 27;12(2):2017-2026 - PubMed
  58. Chem Soc Rev. 2020 Jun 7;49(11):3262-3277 - PubMed
  59. J Am Chem Soc. 2007 Dec 19;129(50):15615-22 - PubMed
  60. AMB Express. 2019 Oct 15;9(1):165 - PubMed
  61. Nat Rev Drug Discov. 2010 Oct;9(10):804-20 - PubMed
  62. J Nanobiotechnology. 2018 Mar 30;16(1):34 - PubMed
  63. Nature. 1984 May 3-9;309(5963):30-3 - PubMed
  64. Biopolymers. 2013 Nov;100(6):675-86 - PubMed
  65. Angew Chem Int Ed Engl. 2021 Jan 25;60(4):1686-1688 - PubMed
  66. Molecules. 2019 Mar 07;24(5): - PubMed
  67. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):15919-24 - PubMed
  68. Adv Drug Deliv Rev. 2020;157:2-36 - PubMed
  69. Biomaterials. 2018 Jun;167:132-142 - PubMed

Publication Types

Grant support